Immunological monitoring of the tumor immunoenvironment for clinical trials (Q37955680)

25 August 2017

Immunological monitoring of the tumor immunoenvironment for clinical trials (English)

1 reference

25 August 2017

1 reference

Anatoli M Malyguine

1

1 reference

PubMed ID

22080408

25 August 2017

Susan L Strobl

series ordinal

2

1 reference

PubMed ID

22080408

25 August 2017

Michael R Shurin

series ordinal

3

1 reference

25 August 2017

12 November 2011

1 reference

Cancer Immunology, Immunotherapy

25 August 2017

1 reference

25 August 2017

61

1 reference

25 August 2017

2

1 reference

25 August 2017

239-247

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1148-6

25 August 2017

0 references

cites work

The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Quantification of tumor-specific T lymphocytes with the ELISPOT assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

A novel flow cytometric assay for evaluating cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Therapeutic cancer vaccines: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Immune responses to malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Immune infiltration in human tumors: a prognostic factor that should not be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Myeloid-derived suppressor cells in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1148-6

10.1007/S00262-011-1148-6

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22080408